Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

6R-BH4 Pulmonary Arterial Hypertension Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00435331
Recruitment Status : Completed
First Posted : February 14, 2007
Last Update Posted : June 19, 2013
Sponsor:
Collaborators:
National Institutes of Health (NIH)
BioMarin Pharmaceutical
Information provided by (Responsible Party):
Ivan Robbins, Vanderbilt University

Brief Summary:

The purpose of this study is to determine whether the addition of sapropterin dihydrochloride (6R-BH4) to existing treatment has any effect in patients with pulmonary arterial hypertension (PAH). Patients with PAH have low levels of a substance called nitric oxide (NO). Tetrahydrobiopterin (BH4) is a substance produced by the body that is an essential requirement in the formation of NO. NO is thought to be helpful in keeping blood vessels in the lung healthy. 6R-BH4 is an experimental (unproven) medicine made in the lab that is very much like the BH4 that our own body makes. The researchers are investigating whether 6R-BH4 can be added safely to current treatment for PAH and whether there is any evidence of benefit from its use. The study will take approximately one year to complete from the time recruitment begins.

The primary objective of the study is to evaluate the safety of oral 6R-BH4, administered in escalating doses in addition to standard care, in subjects with pulmonary arterial hypertension (PAH).

The secondary objective of the study is to evaluate change in biochemical markers of endothelial dysfunction and nitric oxide synthetase activity (coupled and uncoupled) in subjects with PAH receiving escalating doses of oral 6R-BH4 in addition to standard care.

The third objective of the study is to evaluate change in biomarkers of disease progression, 6-minute walk (6MW) distance, Borg dyspnea scores, and quality of life (QOL) measures in subjects with PAH receiving escalating doses of oral 6R-BH4 in addition to standard care.


Condition or disease Intervention/treatment Phase
Pulmonary Arterial Hypertension Drug: sapropterin dihydrochloride (6R-BH4) Phase 1

Detailed Description:

The primary objective of the study is to evaluate the safety of oral 6R-BH4, administered in escalating doses in addition to standard care, in subjects with pulmonary arterial hypertension (PAH).

The secondary objective of the study is to evaluate change in biochemical markers of endothelial dysfunction and nitric oxide synthetase activity (coupled and uncoupled) in subjects with PAH receiving escalating doses of oral 6R-BH4 in addition to standard care.

The third objective of the study is to evaluate change in biomarkers of disease progression, 6-minute walk (6MW) distance, Borg dyspnea scores, and quality of life (QOL) measures in subjects with PAH receiving escalating doses of oral 6R-BH4 in addition to standard care.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate the Safety and Efficacy of 6R-BH4 in Subjects With Pulmonary Arterial Hypertension
Study Start Date : March 2008
Actual Primary Completion Date : September 2008
Actual Study Completion Date : October 2008


Arm Intervention/treatment
Experimental: 1
Open Label
Drug: sapropterin dihydrochloride (6R-BH4)
2.5 mg/kg/day for two weeks, 5 mg/kg/day for two weeks, 10 mg/kg/day for four weeks, then 20 mg/kg/day for two days




Primary Outcome Measures :
  1. To evaluate the safety of oral 6R-BH4, administered in escalating doses in addition to standard care, in subjects with pulmonary arterial hypertension (PAH). [ Time Frame: Up to 14 weeks ]

Secondary Outcome Measures :
  1. Change in biochemical markers of endothelial dysfunction and nitric oxide synthetase activity (coupled and uncoupled). [ Time Frame: Up to 14 weeks ]
  2. Change in biomarkers of disease progression, 6-minute walk (6MW) distance, Borg dyspnea scores, and quality of life (QOL) measures. [ Time Frame: Up to 14 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Documented diagnosis of PAH, defined as mean pulmonary arterial pressure > 25 mm Hg (measured by catheter).
  • PAH is primary (idiopathic) or is secondary and caused by collagen vascular disease, congenital heart disease, or thromboembolic disease.
  • Modified New York Heart Association (NYHA) classification I, II, or III that has been stable for at least 8 weeks prior to enrollment.
  • 6MW distance, as performed at screening or within three months (12 weeks) prior to screening, of ≥ 200 and ≤ 500 meters.
  • Receiving stable doses of one or more medications that are approved for treatment of PAH, except for any agents specifically prohibited by this protocol, for a minimum of 12 consecutive weeks before enrollment. Note: anticoagulant therapy can be adjusted according to target INR.
  • Receiving stable doses of concomitant medication for other conditions, except agents specifically prohibited by the protocol.
  • At least 18 years of age and willing and able to complete an informed consent form.
  • Sexually active subjects must be willing to use an acceptable method of contraception while participating in the study.
  • Females of childbearing potential must have a negative pregnancy test at screening and be willing to have additional pregnancy tests during the study.

Exclusion Criteria:

  • Previous treatment with any formulation of BH4.
  • Known allergy or hypersensitivity to any excipient of 6R BH4.
  • History of systemic hypotension, defined as systolic BP < 100 mm Hg and/or diastolic BP < 60 mm Hg.
  • Treatment at screening or perceived need for treatment during the course of the study with any of the following:

    • intravenous epoprostenol
    • inhaled iloprost
    • subcutaneous treprostinil
    • levodopa
    • any PDE 3 inhibitor, such as cilostazol or milrinone
    • any drug known to inhibit folate metabolism, such as methotrexate (eg, TrexallR), tomizine, trimethoprim, sulfanilamide, deoxycoformycin
    • nitrates
  • Diet supplementation with L-arginine or L-citrulline within 30 days of enrollment.
  • Diet supplementation with high doses (> 3 times the recommended daily allowance) of antioxidants, such as Vitamin C.
  • Use of any investigational product or device within 30 days prior to screening, or known requirement for any investigational agent prior to completion of all scheduled study assessments.
  • Known to be positive for human immunodeficiency virus (HIV).
  • An additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the investigator, may significantly interfere with study compliance, including all prescribed evaluations and follow-up activities. Concurrent disease or condition that may interfere with study participation or safety include bleeding disorders, arrhythmia, organ transplant (other than lung), organ failure, current neoplasm, poorly controlled diabetes mellitus, and serious neurological disorders.
  • Serum creatinine > 2.0 mg/dL (180 μM/L) or hepatic enzyme levels more than 2 times the upper limit of normal.
  • Pregnant or lactating at screening, or planning to become pregnant (self or partner) at any time during study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00435331


Locations
Layout table for location information
United States, Tennessee
Vanderbilt Medical Center
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
Vanderbilt University
National Institutes of Health (NIH)
BioMarin Pharmaceutical
Investigators
Layout table for investigator information
Principal Investigator: Ivan M. Robbins, MD Vanderbilt University
Layout table for additonal information
Responsible Party: Ivan Robbins, Ivan Robbins, MD Professor of Medicine, Vanderbilt University
ClinicalTrials.gov Identifier: NCT00435331    
Other Study ID Numbers: WILK1
First Posted: February 14, 2007    Key Record Dates
Last Update Posted: June 19, 2013
Last Verified: June 2013
Keywords provided by Ivan Robbins, Vanderbilt University:
Pulmonary Arterial Hypertension
PPH
Additional relevant MeSH terms:
Layout table for MeSH terms
Familial Primary Pulmonary Hypertension
Hypertension
Vascular Diseases
Cardiovascular Diseases
Hypertension, Pulmonary
Lung Diseases
Respiratory Tract Diseases
Verapamil
Anti-Arrhythmia Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Vasodilator Agents